medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2016, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2016; 61 (3)

Metabolic syndrome in Mexican women with systemic lupus erythematosus

Fuentes HMN, Andrade OL, Irazoque PF

Language: Spanish
References: 31
Page: 166-172
PDF size: 226.64 Kb.


ABSTRACT

Systemic lupus erythematosus patients have increased cardiovascular risk. This can be as high as five times compared to the general population. As metabolic syndrome and insulin resistance are predictive of cardiovascular events both in the general population and in patients with autoimmune diseases. Objective: This work aimed to evaluate the prevalence of metabolic syndrome and insulin resistance in women with systemic lupus erythematosus and to investigate its relationship with demographic, clinical and therapeutic factors. An observational, descriptive and cross-sectional study was done, including female patients with systemic lupus erythematosus (American College of Rheumatology, 1997). Demographic, clinical, cardiovascular, serological and therapeutic characteristics of the patients were evaluated. Metabolic syndrome was defined using the National Cholesterol Education Program Adult Treatment Panel III 2005 criteria and insulin resistance as insulin resistance homeostasis model assessment › 2.5. Results: A total of 60 patients were included, mean age was 43.4 years, and mean duration of the disease, 10.6 years; 70% were overweight or obese. We found metabolic syndrome in 43.6% and insulin resistance in 41.7%; 18.3% patients had insulin resistance without metabolic syndrome criteria. Only two patients had a cardiovascular event history. We found a correlation between metabolic syndrome and lupus nephritis (p = 0.036), cyclophosphamide (p = 0.001) and mycophenolate treatment (p = 0.004). The prevalence of metabolic syndrome and insulin resistance was higher compared to the international literature but similar to the reports for our country. Positive correlation with lupus nephritis and immunosuppression treatments reflects the higher risk in patients with more severe manifestations. The racial, metabolic and clinical characteristics of lupus in Mexican patients highlight the need of an early evaluation and prompt treatment of metabolic syndrome.


REFERENCES

  1. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010; 39 (4): 257-268.

  2. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976; 60 (2): 221-225.

  3. Manzi S, Meilahn EN, Raire JE ,Conte CG, Medsger TA Jr, Jansen-McWilliams L et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997; 145 (5): 408-415.

  4. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44 (10): 2331-2337.

  5. Zimmeta P, Alberti G, Serrano-Ríos M. Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: fundamento y resultados. Rev Esp Cardiol. 2005; 58 (12): 1371-1376.

  6. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49 (4): 403-414.

  7. Bruce IN. “Not only...but also”: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005; 44 (12): 1492-1502.

  8. El-Magadmi M, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM et al. Hyperinsulinaemia, insulin resistance and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006; 33 (1): 50-56.

  9. Tso TK, Huang WN. Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus. Rheumatol Int. 2009; 29 (7): 735-742.

  10. Rojas-Martínez R, Aguilar-Salinas CA, Jiménez-Corona A, Gómez-Pérez FJ, Barquera S, Lazcano-Ponce E. Prevalence of obesity and metabolic syndrome components in Mexican adults without type 2 diabetes or hypertension. Salud Pública Mex. 2012; 54 (1): 7-12.

  11. Salas R, Bibiloni M del M, Ramos E, Villarreal JZ, Pons A, Tur JA et al. Metabolic syndrome prevalence among Northern Mexican adult population. PLoS One. 2014; 9 (8): e105581.

  12. Parker B, Bruce IN. The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am. 2010; 36 (1): 81-97.

  13. Bultink IE, Turkstra F, Diamant M, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol. 2008; 26 (1): 32-38.

  14. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007; 66 (2): 208-214.

  15. Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013; 72 (8): 1308-1314.

  16. Parker B, Ahmad Y, Shelmerdine J, Edlin H, Yates AP, Teh LS et al. An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus. 2011; 20 (14): 1459-1465.

  17. Zonana-Nacach A, Santana-Sahagún E, Jiménez-Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol. 2008; 14 (2): 74-77.

  18. Guzmán J, Cardiel MH, Arce-Salinas A, Sánchez-Guerrero J, Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol. 1992; 19 (10): 1551-1558.

  19. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol. 2000; 27 (2): 373-376.

  20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112 (17): 2735-2752.

  21. Gheita TA, Raafat HA, Sayed S, El-Fishawy H, Nasrallah MM, Abdel-Rasheed E. Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus. Effect on carotid intima-media thickness. Z Rheumatol. 2013; 72 (2): 172-177.

  22. Vilar MJ, Azevedo GD, Gadelha RG. Prevalence of metabolic syndrome and its components in Brazilian women with systemic lupus erythematosus: implications for cardiovascular risk. Ann Rheum Dis. 2006; 65 (Suppl 2): 362.

  23. Vadacca M, Margiotta D, Rigon A, Cacciapaglia F, Coppolino G, Amoroso A et al. Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol. 2009; 36 (2): 295-297.

  24. Bellomio V, Spindler A, Lucero E, Berman A, Sueldo R, Berman H et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus. 2009; 18 (11): 1019-1025.

  25. Negron AM, Molina MJ, Mayor AM, Rodríguez VE, Vilá LM. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus. 2008; 17 (4): 348-354.

  26. Sabio JM, Zamora-Pasadas M, Jiménez-Jáimez J, Albadalejo F, Vargas-Hitos J, Rodríguez del Aguila MD et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus. 2008; 17 (9): 849-859.

  27. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care. 2004; 27 (10): 2444-2449.

  28. Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae SC et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2014; 0: 1-7. doi: 10.1136/annrheumdis-2013-203933.

  29. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002; 25 (10): 1790-1794.

  30. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003; 108 (4): 414-419.

  31. Hong Y, Jin X, Mo J, Lin HM, Duan Y, Pu M et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality —results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med. 2007; 262 (1): 113-122.




2020     |     www.medigraphic.com